Skip to content
Altius – Lifestyle
Author:
Revive Therapeutics Ltd.
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
September 15, 2026
Revive Therapeutics Announces Proposed Shares for Debt Settlement
August 19, 2026
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
August 19, 2026
Revive Therapeutics Reports Grant of Options
August 14, 2026
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
May 20, 2026